ABSTRACT
Patients with inherited mucocutaneous bleeding (MCB) pose frequent and significant diagnostic challenges. Bleeding symptoms are frequent among the otherwise healthy population, and the clinical distinction between normal subjects and patients with genuine bleeding disorders is complex. Screening or global laboratory assays are nonspecific and have low sensitivity to detect mild bleeding disorders. Moreover, there are inherent difficulties in diagnosing von Willebrand disease and platelet function defects, the best-characterized and most frequent disorders of primary hemostasis. On the other hand, some patients with moderate to severe clotting factor deficiencies and those with increased fibrinolysis usually present with MCB. Finally, in a significant proportion of patients, the definitive diagnosis is not possible even after an extensive laboratory workup. This article reviews the clinical and laboratory approach to the diagnosis of patients presenting with MCB, the limitations of the available methodologies to evaluate the clinical significance of bleeding, and the diagnostic yield of global and specific hemostasis tests used to investigate these patients.
KEYWORDS
Mucocutaneous bleeding - disorders of primary hemostasis - laboratory diagnosis - platelet function testing
REFERENCES
-
1
Sadler J E.
Von Willebrand disease type 1: a diagnosis in search of a disease.
Blood.
2003;
101
2089-2093
-
2
Friberg B, Orno A K, Lindgren A, Lethagen S.
Bleeding disorders among young women: a population-based prevalence study.
Acta Obstet Gynecol Scand.
2006;
85
200-206
-
3
Mauser Bunschoten E P, van Houwelingen J C, Sjamsoedin Visser E J et al..
Bleeding symptoms in carriers of hemophilia A and B.
Thromb Haemost.
1988;
59
349-352
-
4
Nosek-Cenkowska B, Cheang M S, Pizzi N J, Israels E D, Gerrard J M.
Bleeding/bruising symptomatology in children with and without bleeding disorders.
Thromb Haemost.
1991;
65
237-241
-
5
Rodeghiero F, Castaman G, Tosetto A et al..
The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study.
J Thromb Haemost.
2005;
3
2619-2626
-
6
Quiroga T, Goycoolea M, Panes O et al..
High prevalence of bleeders of unknown cause among patients with inherited mucocutaneous bleeding. A prospective study of 280 patients and 299 controls.
Haematologica.
2007;
92
357-365
-
7
Tosetto A, Castaman G, Rodeghiero F.
Assessing bleeding in von Willebrand disease with bleeding score.
Blood Rev.
2007;
21
89-97
-
8
McKay H, Derome F, Haq M A et al..
Bleeding risks associated with inheritance of the Quebec platelet disorder.
Blood.
2004;
104
159-165
-
9
Sramek A, Eikenboom J C, Briet E, Vandenbroucke J P, Rosendaal F R.
Usefulness of patient interview in bleeding disorders.
Arch Intern Med.
1995;
155
1409-1415
-
10
Bolton-Maggs P H, Patterson D A, Wensley R T, Tuddenham E G.
Definition of the bleeding tendency in factor XI-deficient kindreds—a clinical and laboratory study.
Thromb Haemost.
1995;
73
194-202
-
11
Montgomery R R.
von Willebrand disease—the relevance of history.
J Thromb Haemost.
2005;
3
2617-2618
-
12
Tosetto A, Rodeghiero F, Castaman G et al..
A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD).
J Thromb Haemost.
2006;
4
766-773
-
13
Kadir R A, Economides D L, Sabin C A, Owens D, Lee C A.
Frequency of inherited bleeding disorders in women with menorrhagia.
Lancet.
1998;
351
485-489
-
14
Dilley A, Drews C, Miller C et al..
von Willebrand disease and other inherited bleeding disorders in women with diagnosed menorrhagia.
Obstet Gynecol.
2001;
97
630-636
-
15
Saxena R, Gupta M, Gupta P K et al..
Inherited bleeding disorders in Indian women with menorrhagia.
Haemophilia.
2003;
9
193-196
-
16
Philipp C S, Dilley A, Miller C H et al..
Platelet functional defects in women with unexplained menorrhagia.
J Thromb Haemost.
2003;
1
477-484
-
17
Shankar M, Chi C, Kadir R A.
Review of quality of life: menorrhagia in women with or without inherited bleeding disorders.
Haemophilia.
2008;
14
15-20
-
18
Mikhail S, Varadarajan R, Kouides P.
The prevalence of disorders of haemostasis in adolescents with menorrhagia referred to a haemophilia treatment centre.
Haemophilia.
2007;
13
627-632
-
19
Rodeghiero F, Tosetto A, Castaman G.
How to estimate bleeding risk in mild bleeding disorders.
J Thromb Haemost.
2007;
5(Suppl 1)
157-166
-
20
Tosetto A, Castaman G, Rodeghiero F.
Bleeding scores in inherited bleeding disorders: clinical or research tools?.
Haemophilia.
2008;
14
415-422
-
21
Favaloro E J.
Investigating people with mucocutaneous bleeding suggestive of primary hemostatic defects: a low likelihood of a definitive diagnosis?.
Haematologica.
2007;
92
292-296
-
22
Burns E R, Lawrence C.
Bleeding time. A guide to its diagnostic and clinical utility.
Arch Pathol Lab Med.
1989;
113
1219-1224
-
23
Rodgers R P, Levin J.
A critical reappraisal of the bleeding time.
Semin Thromb Hemost.
1990;
16
1-20
-
24
Lind S E.
The bleeding time does not predict clinical bleeding.
Blood.
1991;
77
2547-2552
-
25
Triplett D A.
The bleeding time. Neither pariah or panacea.
Arch Pathol Lab Med.
1989;
113
1207-1208
-
26
Fressinaud E, Veyradier A, Truchaud F et al..
Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases.
Blood.
1998;
91
1325-1331
-
27
Cattaneo M, Federici A B, Lecchi A et al..
Evaluation of the PFA-100® system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease.
Thromb Haemost.
1999;
82
35-39
-
28
Dean J A, Blanchette V S, Carcao M D et al..
Von Willebrand disease in a pediatric-based population – Comparison of type 1 diagnostic criteria and use of the PFA-100® and a von Willebrand factor/collagen binding assay.
Thromb Haemost.
2000;
84
401-409
-
29
Schlammadinger A, Kerényi A, Muszbek L, Boda Z.
Comparison of the O'Brien filter test and the PFA-100 platelet analyzer in the laboratory diagnosis of von Willebrand's disease.
Thromb Haemost.
2000;
84
88-92
-
30
Favaloro E J, Kershaw G, Bukuya M, Hertzberg M, Koutts J.
Laboratory diagnosis of von Willebrand disorder (VWD) and monitoring of DDAVP therapy: efficacy of the PFA-100® and VWF:CBA as combined diagnostic strategies.
Haemophilia.
2001;
7
180-189
-
31
Favaloro E J.
Clinical application of the PFA-100®
.
Curr Opin Hematol.
2002;
9
407-415
-
32
Cattaneo M, Lecchi A, Agati B, Lombardi R, Zighetti M L.
Evaluation of platelet function with the PFA-100® system in patients with congenital defects of platelet secretion.
Thromb Res.
1999;
96
213-217
-
33
Kerényi A, Schlammadinger A, Ajzner E et al..
Comparison of PFA-100 closure time and template bleeding time of patients with inherited disorders causing defective platelet function.
Thromb Res.
1999;
96
487-492
-
34
Cattaneo M.
Inherited platelet-based bleeding disorders.
J Thromb Haemost.
2003;
1
1628-1636
-
35
Rao A K.
Inherited defects in platelet signalling mechanisms.
J Thromb Haemost.
2003;
1
671-681
-
36
Hayward C PM, Harrison P, Cattaneo M, Ortel T L, Rao A K.
The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis. Platelet function analyzer (PFA)-100 closure timeâ in the evaluation of platelet disorders and platelet function.
J Thromb Haemost.
2006;
4
312-319
-
37
Quiroga T, Goycoolea M, Muñoz B et al..
Template bleeding time and PFA-100® have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages: comparative study in 148 patients.
J Thromb Haemost.
2004;
2
892-898
-
38
Podda G M, Bucciarelli P, Lussana F, Lecchi A, Cattaneo M.
Usefulness of PFA-100® testing in the diagnostic screening of patients with suspected abnormalities of hemostasis: comparison with the bleeding time.
J Thromb Haemost.
2007;
5
2393-2398
-
39
Acharya S S, Coughlin A, Dimichele D M. and the North American Rare Bleeding Disorder Study Group .
Rare bleeding disorder registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemia.
J Thromb Haemost.
2004;
2
248-256
-
40
Peyvandi F, Duga S, Akhavan S, Mannucci P M.
Rare coagulation deficiencies.
Haemophilia.
2002;
8
308-321
-
41
Plug I, Mauser-Bunschoten E P, Bröcker-Vriends A H et al..
Bleeding in carriers of haemophilia.
Blood.
2006;
108
52-56
-
42 Konkle B A. Clinical approach to the bleeding patient. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ Hemostasis and Thrombosis. Basic Principles & Clinical Practice. 5th ed. Philadelphia, PA; Lippincott Williams & Wilkins 2006: 1147-1158
-
43
Gomez K, Bolton-Maggs P.
Factor XI-deficiency.
Haemophilia.
2008;
27
, [Epub ahead of print]
-
44
Kahr W H, Zheng S, Sheth P M et al..
Platelets from patients with the Quebec platelet disorder contain and secrete abnormal amounts of urokinase-type plasminogen activator.
Blood.
2001;
98
257-265
-
45
Griffin G C, Mammen E F, Sokol R J, Perrotta A L, Stoyanovich A, Abilgaard C F.
Alpha 2-antiplasmin deficiency. An overlooked cause of hemorrhage.
Am J Pediatr Hematol Oncol.
1993;
15
328-330
-
46
Diéval J, Nguyen G, Gross S, Delobel J, Kruithof E K.
A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1.
Blood.
1991;
77
528-532
-
47
Lee M H, Vosburgh E, Anderson K, McDonagh J.
Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding.
Blood.
1993;
81
2357-2362
-
48
Takahashi Y, Tanaka T, Minowa H et al..
Hereditary partial deficiency of plasminogen activator inhibitor-1 associated with a lifelong bleeding tendency.
Int J Hematol.
1996;
64
61-68
-
49
Fay W P, Parker A C, Condrey L R, Shapiro A D.
Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene.
Blood.
1997;
90
204-208
-
50
Favaloro E J.
Laboratory identification of von Willebrand disease: technical and scientific perspectives.
Semin Thromb Hemost.
2006;
32
456-471
-
51
Favaloro E J, Bonar B, Kershaw G et al..
Reducing errors in identification of von Willebrand disease: the experience of the Royal College of Pathologists of Australasia quality assurance program.
Semin Thromb Hemost.
2006;
32
505-513
-
52
Abildgaard C F, Suzuki Z, Harrison J, Jefcoat K, Zimmerman T S.
Serial studies in von Willebrand's disease: variability versus “variants”.
Blood.
1980;
56
712-716
-
53
Shankar M, Lee C A, Sabin C A, Economides D L, Kadir R A.
Von Willebrand disease in women with menorrhagia: a systematic review.
BJOG.
2004;
111
734-740
-
54
Quiroga T, Pérez M, Rodríguez S et al..
Skin and mucous membrane hemorrhages. Clinical assessment and relative frequency of hereditary diseases in the Chilean population.
Rev Med Chil.
1997;
125
409-418
-
55
Gupta P K, Charan V D, Saxena R.
Spectrum of Von Willebrand disease and inherited platelet function disorders amongst Indian bleeders.
Ann Hematol.
2007;
86
403-407
-
56
Hayward C PM.
Inherited platelet disorders.
Curr Opin Hematol.
2003;
10
362-368
-
57
Harrison P.
Progress in the assessment of platelet function.
Br J Haematol.
2000;
111
733-744
-
58
Moffat K A, Ledford-Kraemer M R, Nichols W L, Hayward C PM.
Variability in clinical laboratory practice in testing for disorders of platelet function: results of two surveys of the North America Specialized Coagulation Laboratory Association.
Thromb Haemost.
2005;
93
549-553
-
59
Born G V.
Aggregation of blood platelets by adenosine diphosphate and its reversal.
Nature.
1962;
194
927-929
-
60
Platelet aggregation: part II. Some results from a new method of study.
J Clin Pathol.
1962;
15
452-455
-
61
Michelson A D, Frelinger III A L, Furman M I.
Current options in platelet function testing.
Am J Cardiol.
2006;
98
4N-10N
-
62
Zhou L, Schmaier A H.
Platelet aggregation testing in platelet-rich plasma: description of procedures with the aim to develop standards in the field.
Am J Clin Pathol.
2005;
123
172-183
-
63
Breddin H K.
Can platelet aggregometry be standardized?.
Platelets.
2005;
16
151-158
-
64
Mannucci P M, Duga S, Peyvandi F.
Recessively inherited coagulation disorders.
Blood.
2004;
104
1243-1252
-
65
Agren A, Wiman B, Stiller V et al..
Evaluation of low PAI-1 activity as a risk factor for hemorrhagic diathesis.
J Thromb Haemost.
2006;
4
201-208
-
66
Agren A, Wiman B, Schulman S.
Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity.
Blood Coagul Fibrinolysis.
2007;
18
657-660
-
67
Parkin J D, Smith I L, O'Neill A I, Ibrahim K MA, Butcher L A.
Mild bleeding disorders. A clinical and laboratory study.
Med J Aust.
1992;
156
614-617
-
68
Wuillemin W A, Gasser K M, Zeerleder S S et al..
Evaluation of a platelet function analyzer (PFA-100®) in patients with a bleeding tendency.
Swiss Med Wkly.
2002;
132
443-448
-
69
Sandoval C, Dong S, Visintainer P et al..
Clinical and laboratory features of 178 children with recurrent epistaxis.
J Pediatr Hematol Oncol.
2002;
24
47-49
-
70
Gerrard J M, Duta E, Nosek-Cenkowska B, Singhroy S, Cheang M, Kobrinsky N L.
A role for prostacyclin in bruising symptomatology.
Pediatrics.
1992;
90
33-36
-
71
Simon D I, Stamler J S, Loh E, Loscalzo J, Francis S A, Creager M A.
Effects of nitric oxide synthase inhibition on bleeding time in humans.
J Cardiovasc Pharmacol.
1995;
26
339-342
-
72
Ubatuba F B, Moncada S, Vane J R.
The effect of prostacyclin (PGI2) on platelet behaviour. Thrombus formation in vivo and bleeding time.
Thromb Haemost.
1979;
41
425-435
-
73
Brouwer J L, Veeger N J, Kluin-Nelemans H C, van der Meer J.
The pathogenesis of venous thromboembolism: evidence for multiple interrelated causes.
Ann Intern Med.
2006;
145
807-815
-
74 Rosendaal F R. Venous thrombosis: the role of genes, environment, and behavior. Washington, DC; Hematology, American Society of Hematology, Educational Program 2005: 1-12
-
75
Ruggeri Z M, Orje J N, Habermann R, Federici A B, Reininger A J.
Activation-independent platelet adhesion and aggregation under elevated shear stress.
Blood.
2006;
108
1903-1910
-
76
Brogren H, Karlsson L, Andersson M, Wang L, Erlinge D, Jern S.
Platelets synthesize large amounts of active plasminogen activator inhibitor 1.
Blood.
2004;
104
3943-3948
-
77
Panes O, Matus V, Sáez C G, Quiroga T, Pereira J, Mezzano D.
Human platelets synthesize and express functional tissue factor.
Blood.
2007;
109
5242-5250
Diego MezzanoM.D.
Department of Hematology-Oncology, School of Medicine, Pontificia Universidad Católica de Chile
P.O. Box 114-D, Santiago, Chile
Email: dmezzano@med.puc.cl
